> Details
Voss, Michael G.;
Cuthbertson, David D.;
Cleves, Mario M.;
Xu, Ping;
Evans-Molina, Carmella;
Palmer, Jerry P.;
Redondo, Maria J.;
Steck, Andrea K.;
Lundgren, Markus;
Larsson, Helena;
Moore, Wayne V.;
Atkinson, Mark A.;
Sosenko, Jay M.;
Ismail, Heba M.;
Greenbaum, Carla J.;
Anderson, Mark;
Atkinson, Mark A.;
Bosi, Emanuele;
Brusko, Todd M.;
Buckner, Jane;
Clements, Mark;
Colman, Peter G.;
Daniels, Mark;
DiMeglio, Linda;
[...]
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
Sharing
Reference
management
Direct link
Bookmarks
Remove from
bookmarks
Share this by email
Share this on Twitter
Share this on Facebook
Share this on Whatsapp
- Media type: E-Article
- Title: Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
- Contributor: Voss, Michael G.; Cuthbertson, David D.; Cleves, Mario M.; Xu, Ping; Evans-Molina, Carmella; Palmer, Jerry P.; Redondo, Maria J.; Steck, Andrea K.; Lundgren, Markus; Larsson, Helena; Moore, Wayne V.; Atkinson, Mark A.; Sosenko, Jay M.; Ismail, Heba M.; Greenbaum, Carla J.; Anderson, Mark; Atkinson, Mark A.; Bosi, Emanuele; Brusko, Todd M.; Buckner, Jane; Clements, Mark; Colman, Peter G.; Daniels, Mark; DiMeglio, Linda; [...]
- imprint: American Diabetes Association, 2021
- Published in: Diabetes Care
- Language: English
- DOI: 10.2337/dc21-0226
- ISSN: 0149-5992; 1935-5548
- Keywords: Advanced and Specialized Nursing ; Endocrinology, Diabetes and Metabolism ; Internal Medicine
- Origination:
- Footnote:
- Description: <jats:sec> <jats:title>OBJECTIVE</jats:title> <jats:p>To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes.</jats:p> </jats:sec> <jats:sec> <jats:title>RESEARCH DESIGN AND METHODS</jats:title> <jats:p>We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS</jats:title> <jats:p>In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose &gt;30 min and time to peak C-peptide &gt;60 min (P &lt; 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P &lt; 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS</jats:title> <jats:p>In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression.</jats:p> </jats:sec>
- Access State: Open Access